Clinical Trials Logo

ABSSSI clinical trials

View clinical trials related to ABSSSI.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04919954 Completed - Diabetes Clinical Trials

Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

Start date: July 1, 2021
Phase: Phase 1
Study type: Interventional

This study will determine the tissue penetration of a broad-spectrum orally bioavailable carbapenem, tebipenem pivoxil hydrobromide (SPR994) (Spero Therapeutics, Inc.), into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will be compared with a group of healthy volunteer control participants.